The findings in our patient support these previous findings [5-7] of dose-dependent improvement in glycemic control and insulin secretion capacity by sitagliptin observed in type 2 diabetes, and further show its effect on PNDM. The gene discussed is INS; the disease is type 2 diabetes mellitus.